Hero image

One focused program. One clear goal

CP-012 is our sole clinical-stage program, designed to address morning motor symptoms in people living with Parkinson's disease.

Pipeline overview

* License to formulation technology with BDD Pharma, UK
SMOL = Small Molecule

Parkinson's disease

Parkinson's disease is one of the fastest-growing neurological disorders worldwide, affecting more than 8.5 million people globally (WHO, 2019). It is characterized by the progressive loss of dopamine-producing neurons in the brain, leading to tremor, rigidity, slowness of movement and a range of non-motor symptoms.

Levodopa, typically combined with carbidopa, has been the gold-standard treatment for Parkinson's motor symptoms for more than 50 years. However, levodopa has a short half-life, and as the disease progresses, the benefit of each dose becomes shorter. Patients often need increasingly frequent dosing, and symptoms return as medication levels decline. These periods of reduced treatment effect are known as OFF periods.

Teaser image

The unmet need: nights and mornings

For many people with Parkinson's disease, the most difficult part of the day begins before they get out of bed. The overnight interval is typically the longest period without a new dose of levodopa. As medication levels decline, patients may experience:

• Nocturnal immobility – Difficulty turning in bed, getting up during the night and maintaining uninterrupted sleep.

• Morning OFF (early morning akinesia) – Waking up with stiffness and impaired mobility, often having to wait for the first morning dose to take effect before being able to move freely.

Studies suggest that approximately 60% of people with Parkinson's disease experience early morning akinesia, while nocturnal immobility is also highly prevalent (Rizos et al., 2014). These symptoms may be accompanied by pain, anxiety, low mood and other non-motor complications, and may affect quality of life for patients and caregivers.

Despite available treatment options, managing symptoms during the night and early morning remains a significant challenge. Treatments taken after waking may relieve morning OFF symptoms, but do not necessarily prevent patients from waking up in an OFF state.

The information on this website is for general information only and is not intended as medical advice. Patients should consult their physician about their treatment.

Teaser image

Early morning OFF is common, appears early in the disease and has a real impact on patients’ and caregivers’ daily lives. Treating it requires levodopa to be working before the patient wakes. That is the principle behind
CP-012.

Anne Birk Østerskov, MD
Chief Medical Officer

CP-012: our approach

CP-012 is an investigational, delayed-release, dual-pulse levodopa/carbidopa tablet based on BDD Pharma's OralogiK™ drug-delivery technology.

Designed to be taken at bedtime in addition to existing Parkinson's medication, CP-012 aims to deliver levodopa during the late night and early morning hours, targeting the period when medication levels may otherwise be insufficient.

By providing a delayed release of levodopa before waking, CP-012 is being developed with the goal of reducing morning OFF symptoms and improving early morning mobility.

Key features

  • Targeting symptoms before waking: Designed to deliver levodopa in the hours before patients wake up, rather than relying on medication taken after symptoms appear.
  • Established active ingredients: Combines levodopa/carbidopa, the gold-standard therapy for Parkinson's motor symptoms, with an innovative delayed-release formulation.
  • Simple to use: A bedtime tablet designed to complement existing treatment, without the need for pumps, injections or external devices.

CP-012 is an investigational product. It has not been approved by any regulatory authority, and its safety and efficacy have not been established.

Explainer video

Watch: How CP-012 could change the Parkinson's morning